Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

Anne D. Lewis, Ruju Chen, David C. Montefiori, Philip R. Johnson, K. Reed Clark

    Research output: Contribution to journalArticle

    88 Scopus citations

    Abstract

    Although several human immunodeficiency virus (HIV) vaccine approaches have elicited meaningful antigen-specific T-cell responses in animal models, no single vaccine candidate has engendered antibodies that broadly neutralize primary isolates of HIV type 1 (HIV-1). Thus, there remains a significant gap in the design of HIV vaccines. To address this issue, we exploited the existence of rare human monoclonal antibodies that have been isolated from HIV-infected individuals. Such antibodies neutralize a wide array of HIV-1 field isolates and have been shown to be effective in vivo. However, practical considerations preclude the use of antibody preparations as a prophylactic passive immunization strategy in large populations. Our concept calls for an antibody gene of choice to be transferred to muscle where the antibody molecule is synthesized and distributed to the circulatory system. In these experiments, we used a recombinant adeno-associated virus (rAAV) vector to deliver the gene for the human antibody IgG1b12 to mouse muscle. Significant levels of HIV-neutralizing activity were found in the sera of mice for over 6 months after a single intramuscular administration of the rAAV vector. This approach allows for predetermination of antibody affinity and specificity prior to "immunization" and avoids the need for an active Immoral immune response against the HIV envelope protein.

    Original languageEnglish (US)
    Pages (from-to)8769-8775
    Number of pages7
    JournalJournal of virology
    Volume76
    Issue number17
    DOIs
    StatePublished - 2002

    ASJC Scopus subject areas

    • Microbiology
    • Immunology
    • Insect Science
    • Virology

    Fingerprint Dive into the research topics of 'Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer'. Together they form a unique fingerprint.

  • Cite this